Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Brain Tumor

Brain Tumor

17

Pipeline Programs↗

35

Active Trials↗

11

Companies Involved↗

Brain Tumor is an emerging landscape with 17 programs across 11 companies. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

36/100

Mech. Concentration

25/100

Completion Rate

86/100

Attrition Rate

7/100

Pipeline

Programs by Phase

Preclinical4

Zotiraciclib

National Cancer Institute (NCI)

Panitumumab-Irdye800

Stanford University

Panitumumab

Amgen

Bcnu

General Oncology, Inc.

Phase 14

TAA-T

Catherine Bollard

Temozolomide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Letrozole

Novartis

HER2-Specific T Cells

Baylor College of Medicine

Phase 23

Abemaciclib

Eli Lilly

Belvarafenib

Roche

DNX-2401

DNAtrix, Inc.

Phase 36

Pembrolizumab

Merck & Co.

Atezolizumab

Roche

Cemiplimab

Regeneron

Nivolumab

Bristol-Myers Squibb

Iptilimumab

InSightec

Approved

No programs

Analysis

Modality Breakdown

14programs

Small molecule857%

Monoclonal antibody643%

Modality classified for 94% of 17 pipeline programs.

Analysis

Trial Status

74

clinical trials

Completed30 · 41%

Recruiting20 · 27%

Active, not recruiting8 · 11%

Not yet recruiting7 · 9%

Terminated5 · 7%

Unknown status4 · 5%

Clinical Trials

Trial Activity

74 trials

Development of Magnetic Resonance Fingerprinting for Characterization of Brain Tumors After Radiotherapy

Recruiting·CCase Comprehensive Cancer Center·Preclinical·NCT06101069·90 enrolled

Treatment Response Assessment Maps (TRAMs) in the Delineation of Radiation Necrosis From Tumor Progression After Stereotactic Radiation in Patients With Brain Metastases: A Prospective Study

Recruiting·BBrigham and Women's Hospital·Preclinical·NCT04033497·101 enrolled

FearLess in Neuro-Oncology

Recruiting·VVirginia Commonwealth University·Preclinical·NCT06989086·112 enrolled

ASSESSMENT OF PHYSICAL PERFORMANCE AND QUALITY OF LIFE IN CHILDREN WITH BRAIN TUMORS.

Recruiting·—·N/A·NCT07810673·60 enrolled

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Recruiting·National Cancer Institute (NCI)·Preclinical·NCT05588141·96 enrolled

Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy

Recruiting·MMassachusetts General Hospital·Preclinical·NCT03286335·100 enrolled

A Randomized Pivotal Study Assessing the Safety and Efficacy of Targeted Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound During the Standard of Care Treatment of Brain Metastases of Non-small Cell Lung Cancer (NSCLC) Origin

Recruiting·IInSightec·Phase 3·NCT05317858·30 enrolled

A Phase 0/1 Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination With Standard Therapy in Recurrent High Grade Gliomas

Recruiting·UUniversity of Cincinnati·Phase 1·NCT03122197·39 enrolled

Ommaya Reservoir Placement for Brain Tumor Biomarker Access

Recruiting·MMayo Clinic·Preclinical·NCT04692337·100 enrolled

B6 Administration for Levetiracetam-Associated Neurobehavioral Changes and Epilepsy (BALANCE)

Recruiting·DDuke University·Preclinical·NCT07271966·50 enrolled

A Multicenter Observational Study of GammaTile™ Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms

Recruiting·GGT Medical Technologies, Inc.·N/A·NCT04427384·600 enrolled

Evaluation of the Neurologic Assessment in Pediatric Neuro-Oncology (pNANO)

Recruiting·UUniversity of Wisconsin, Madison·N/A·NCT06981156·252 enrolled

An Exploratory Phase 2 Study for Evaluating CNS Efficacy of Belvarafenib in Patients With BRAF-Altered Solid Tumors

Recruiting·SSamsung Medical Center·Phase 2·NCT07688356·30 enrolled

A Phase IV and Observational Study to Evaluate Safety and Effectiveness of Temozolomide (Amitzo, NanoAlvand) Therapy in in Patients With Grade III and IV Glioma Tumors

Recruiting·NNanoAlvand·N/A·NCT07675070·100 enrolled

Phase 1/Phase 2, Open Label Study Evaluating the Safety, Dosing and Efficacy of Panitumumab IRDye800 as an Optical Imaging Agent to Detect Pediatric Neoplasms During Neurosurgical Procedures

Recruiting·SStanford University·Preclinical·NCT04085887·12 enrolled

Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)